Theralase Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is reminding shareholders of its Annual General and Special Meeting ("AGSM") to take place on Wednesday, June 11th, 2025 at 4:30 pm ET at the Company's head office located at 41 Hollinger Road, Toronto, Ontario, Canada.
In order to help make the AGSM more interactive for those shareholders, who are unable to attend in person, immediately after the formal part of the AGSM has concluded, Theralase® will be hosting a virtual presentation at 5:15 pm ET, which will include a corporate presentation of the Company's strategic objectives for 2025 and 2026, as well as a question and answer period to provide an opportunity for shareholders to have their questions addressed.
The corporate power point presentation and question and answer period will end at 6:30 pm ET.
Zoom Meeting Link: https://us02web.zoom.us/j/87175139183Webinar ID: 871 7513 9183Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom.
An archived version will be available on the website, the next business day, following the conference call.
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:1.866.THE.LASE (843-5273)416.699.LASE (5273)www.theralase.com
Kristina Hachey, CPAChief Financial Officer X 224khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254481
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Yorkton Equity Group Inc. Announces Normal Course Issuer Bid for Common Shares
EDMONTON, ALBERTA - June 6, 2025 (NEWMEDIAWIRE) - Yorkton Equity Group Inc. ("Yorkton" or the "Company") (TSX.V: YEG) announces its has received TSX Venture Exchange (the "Exchange") approval to commence a normal course issuer bid (the "NCIB") through the facilities of the Exchange to repurchase, for cancellation, up to an aggregate of 5,634,028 common shares of the Company ("Common Shares"), representing approximately 5% of the outstanding Common Shares. The funds used to repurchase the Common Shares under the NCIB will only come from cash provided by operating activities of the Company. The NCIB is expected to commence on June 6, 2025 and will terminate upon the earliest of (i) the Company purchasing 5,634,028 Common Shares, (ii) the Company providing notice of termination of the NCIB, and (iii) on June 5, 2026. The Company believes that, from time to time, the market price of its common shares does not adequately reflect the Company's underlying value and future prospects such that having the ability to purchase the Company's common shares represents an appropriate use of the Company's financial resources and will enhance shareholder value. The Company has engaged Independent Trading Group (ITG), Inc. to act as its broker for the NCIB (the "Broker"). The NCIB will be made through the facilities of the Exchange and the purchase and payment for the Common Shares will be made from the Company's cash that has been generated by its operating activities, at the market price of the Common Shares at the time of acquisition (plus brokerage fees, if any, charged by the Broker). All Common Shares purchased by the Company under the NCIB will be cancelled. To the Company's knowledge, none of the directors, senior officers or insiders of the Company, or any associate of such person, or any associate or affiliate of the Company, has any present intention to sell any securities to the Company during the NCIB. A copy of the Form 5G Notice of Intention to make a Normal Course Issuer Bid filed by the Company with the Exchange in respect of the NCIB can be obtained from the Company upon request without charge. About Yorkton Yorkton Equity Group Inc. is a growth-oriented real estate investment company committed to providing shareholders with growing assets through accretive acquisitions, organic growth, and the active management of multi-family rental properties with significant upside potential. Our current geographical focus is in Alberta and British Columbia with diversified and growing economies, and strong population in-migration. Our business objectives are to achieve growing Net Operating Income ("NOI") and asset values in our multi-family rental property portfolio in strategic markets across Western Canada. The management team at Yorkton Equity Group Inc. has well over 30 years of prior real estate experience in acquiring and managing rental assets. Further information about Yorkton is available on the Company's website at and the SEDAR+ website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information on Yorkton, please contact: Ben Lui, CEOTelephone: (780) 409-8228Email: investors@ Forward-looking information This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of Yorkton. Forward-looking information is based on certain key expectations and assumptions made by the management of Yorkton. Although Yorkton believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Yorkton can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Yorkton disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirement.
Yahoo
2 hours ago
- Yahoo
Treasury Options Skew June 2025
Implied volatility in options on Treasury futures has drifted lower since April, but the skew—particularly in the belly of the curve—remains a focal point. As traders prepare for a data-heavy June, including Non-Farm Payrolls, CPI and the FOMC, the behavior of skew and CVOL in the Ultra 10-Year (UXY) futures complex offers a revealing lens into how rate risk is being priced. Downside skew in Treasury options—especially on 5-Year (FV), 10-Year (TY) and Ultra 10-Year (UXY) futures—remains elevated. TYVY, the CVOL Index for 10-Year Treasury options, has declined from April highs but is still holding in the 115–120 range. Key macro events ahead: Non-Farm Payrolls – Friday, June 6 . Consumer Price Index (CPI) – Wednesday, June 12. FOMC Statement – Wednesday, June 18, 2:00 p.m. ET; press conference at 2:30 p.m. ET. PCE Price Index – Friday, June 27. Despite the decline in overall volatility, downside skew remains persistent, particularly in UXY and FV options. Traders continue to assign higher premiums to puts relative to calls, reflecting structural demand for downside hedges or latent concerns about fiscal risk, policy missteps or supply shocks. As we approach the June 6 jobs report, and especially the June 18 FOMC decision, this skew could be tested. Traders can use CVOL to see TVL or volatility indices for 2-, 5-, 10-Year and Bond futures. For volatility on options like the growing option volume on Ultra 10-Year futures consider QuikVol's QuikSkew analytics. The 2s10s curve steepened in May, reviving interest in conditional curve trades using options to express directional views on curve shape. Options are increasingly being used to express conditional curve trades. Call spreads in FV versus put spreads in UXY. Butterfly structures around inflection points in UXY to capture steepening potential without excessive Vega exposure. TYVY skew, built on deep liquidity from options on 10-Year Note futures, supports this theme. Depending on one's risk management strategy, options on 10-Year Note futures or options on Ultra 10-Year futures retain more downside premium relative to other tenors. We have expanded our suite of Treasury options with the addition of Tuesday and Thursday expiries, significantly enhancing the flexibility of short-dated hedging strategies. This update allows market participants to position tactically around high-impact economic releases such as Non-Farm Payrolls, CPI and FOMC decisions, by accessing expiries available every trading day of the week, two weeks forward. This enhancement is especially valuable in environments with compressed risk windows, intraday volatility bursts, or when event timing doesn't align neatly with the traditional Monday/Wednesday/Friday expiration schedule. The change was detailed in CME Group SER-9566R. With the macro spotlight on June 6 and June 18, options on Treasury futures offer deep insight into how rate risk is being repriced. Skews in UXY options, the behavior of TVL and renewed activity in curve-based option structures all point to a market that sees risk beneath the surface. Whether you're watching TVL or the new Tuesday and Thursday expiries, June will be a month to track the message inside the vol surface. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service. All examples in this report are hypothetical interpretations of situations and are used for explanation purposes only. The views in this report reflect solely those of the author and not necessarily those of CME Group or its affiliated institutions. This report and the information herein should not be considered investment advice or the results of actual market experience. CME Group Inc. does not have control over the content, accuracy, quality, or legality, of any third-party product, service, or content advertised on this webpage. The presence of such advertisements on this webpage does not signify any association, partnership, or endorsement of the third-party or its content by CME Group Inc. Full disclaimer Copyright © 2025 CME Group Inc.
Business Insider
2 hours ago
- Business Insider
iOThree receives Nasdaq notification regarding minimum bid price deficiency
iOThree (IOTR) Limited announced that it has received a written notification from the Nasdaq Stock Market LLC on June 3, 2025, indicating that the Company was not in compliance with the $1.00 closing bid price requirement for the last 30 consecutive business days from April 21, 2025 to June 2, 2025 under the Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker 'IOTR'. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until December 1, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's ordinary shares must be at least $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. Confident Investing Starts Here:
